Tiny mul­ti­omics biotech se­cures for­mer J&J drug, new ex­ecs and new fi­nanc­ing

A new spin­out from Bel­gium’s ar­genx seeks to give new life to a can­di­date once in-li­censed to J&J.

On­coVer­i­ty an­nounced Mon­day af­ter­noon that it had in-li­censed cusat­uzum­ab from ar­genx. The biotech al­so ap­point­ed two new C-suite ex­ec­u­tives and se­cured a $30 mil­lion Se­ries A round.

CEO Max Co­lao joins On­coVer­i­ty af­ter work­ing as Au­rinia’s com­mer­cial chief, and stints at Alex­ion and Am­gen. New CMO Clay Smith has been as­so­ciate chief of the Uni­ver­si­ty of Col­orado’s hema­tol­ogy di­vi­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER